Shenzhen GTJA Investment Group makes sole investment in Chengdu Leadro Biotech A+ round

PUBT · 2d ago
Shenzhen GTJA Investment Group makes sole investment in Chengdu Leadro Biotech A+ round
  • Shenzhen GTJA Investment Group led an A+ private financing round in Chengdu Xianyan Biotech via its Xiamen Ruilu fund.
  • Proceeds to fund clinical development of first-in-class oligonucleotide drug candidates, improve extrahepatic delivery platforms, expand preclinical pipeline.
  • Xianyan, founded in 2022, develops oligonucleotide medicines for chronic cardiometabolic diseases using proprietary delivery, modification, and dual-target technologies.
  • Lead asset LDR2402, an AGT-targeting long-acting antihypertensive, is in Phase II trials in China with quarterly or semiannual dosing potential.
  • LDR1259 siRNA for dyslipidemia received China regulator’s implicit clearance for a clinical trial application in August; additional metabolic program is in Phase I.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen GTJA Investment Group Co Ltd published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.